TruScreen Launches NZ$1.94 Million Renounceable Rights Offer to Accelerate Global Cervical Cancer Screening Expansion
TruScreen Group Limited (ASX: TRU) has launched a 1-for-5 renounceable rights offer priced at NZ$0.013 per share to raise up to approximately NZ$1.943 million, supporting the Company’s global expansion strategy and commercialisation initiatives for its AI-enabled cervical cancer screening technology. The offer price represents a 24% discount to the closing share price on 19 May 2026.
The Company reported FY2026 product sales growth of 42% year-on-year, driven by broader geographic expansion, including first commercial sales into India and Indonesia. TruScreen highlighted significant opportunities across large addressable markets, with India representing 468 million screening-age women and Indonesia 95 million women supported by government-funded screening programmes.
Management noted that funds raised will primarily support regulatory compliance, African market registrations, clinical evidence development, sales and marketing expansion, manufacturing capacity upgrades and working capital. TruScreen also confirmed participation in five UNITAID grant applications targeting cervical cancer screening programmes across 14 high-burden countries, representing a potential revenue opportunity of up to US$18.4 million as consortium lead.
The Company stated that its TruScreen® Ultra technology is designed for low-resource healthcare environments where laboratory infrastructure and specialist pathology services are limited, supporting WHO’s 90-70-90 cervical cancer elimination targets by 2030.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
TruScreen Launches NZ$1.94 Million Renounceable Rights Offer to Accelerate Global Cervical Cancer Screening Expansion
TruScreen Group Limited (ASX: TRU) has launched a 1-for-5 renounceable rights offer priced at NZ$0.013 per share to raise up to approximately NZ$1.943 million, supporting the Company’s global expansion strategy and commercialisation initiatives for its AI-enabled cervical cancer screening technology. The offer price represents a 24% discount to the closing share price on 19 May 2026.
The Company reported FY2026 product sales growth of 42% year-on-year, driven by broader geographic expansion, including first commercial sales into India and Indonesia. TruScreen highlighted significant opportunities across large addressable markets, with India representing 468 million screening-age women and Indonesia 95 million women supported by government-funded screening programmes.
Management noted that funds raised will primarily support regulatory compliance, African market registrations, clinical evidence development, sales and marketing expansion, manufacturing capacity upgrades and working capital. TruScreen also confirmed participation in five UNITAID grant applications targeting cervical cancer screening programmes across 14 high-burden countries, representing a potential revenue opportunity of up to US$18.4 million as consortium lead.
The Company stated that its TruScreen® Ultra technology is designed for low-resource healthcare environments where laboratory infrastructure and specialist pathology services are limited, supporting WHO’s 90-70-90 cervical cancer elimination targets by 2030.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au